Patents Assigned to Bristol-Meyers Squibb Company
  • Patent number: 8202881
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: June 19, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ashok V. Purandare, James W. Grebinski, Amy Hart, Jennifer Inghrim, Gretchen Schroeder, Honghe Wan
  • Patent number: 8119629
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: February 21, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Ronald J. Mattson
  • Patent number: 7772221
    Abstract: There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: August 10, 2010
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Lawrence R. Marcin, Andrew C. Good, Yong-Jin Wu, Dmitry S. Zuev, Richard E. Olson, Nenghui Wang
  • Patent number: 7569578
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: August 4, 2009
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Andrew P. Degnan, Gene M. Dubowchik, John E. Macor, George O. Tora, Prasad V. Chaturvedula
  • Patent number: 7531535
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: May 12, 2009
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Donald J. P. Pinto, Jennifer X. Qiao
  • Patent number: 7504399
    Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine enamine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to a compound of Formula I useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: March 17, 2009
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Tao Wang, John F. Kadow, Zhongxing Zhang, Zhiwei Yin, Nicholas A. Meanwell
  • Patent number: 7504481
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: March 17, 2009
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Liana M. Lee, Michael A. Blanar
  • Patent number: 7432373
    Abstract: The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: October 7, 2008
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Gerard Crispino, Stephanie Barbosa, Junying Fan, Zhen-wei Cai
  • Patent number: 7425550
    Abstract: A compound of formula I is provided having the structure wherein W is as defined herein; X is —CHR5O—; Y is a bond; Z is an aryl or heteroaryl group; and R1, and R2, are as described herein. Further provided is a method for treating diabetes and related diseases employing the above compound, either alone or in combination with another therapeutic agent.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: September 16, 2008
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Philip Sher, Gang Wu, Terry Stouch, Bruce Ellsworth
  • Patent number: 7416876
    Abstract: This invention relates to isolated or recombinant N-CBZ-deprotecting enzyme polypeptides that catalyze the removal of CBZ from CBZ-protected amino acids and alcohols, and variants, modifications, and fragments thereof. Also related are isolated nucleic acids encoding N-CBZ-deprotecting enzyme polypeptides, and variants, modifications, and fragments thereof, as well as vectors and host cells comprising these nucleic acids. The invention also relates to methods of obtaining isolated nucleic acids, polypeptides, and antibodies, and methods of using polypeptides in various reactions for industrial or pharmaceutical applications.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: August 26, 2008
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Venkata B. Nanduri, Ramesh N. Patel, Steven L. Goldberg, Robert M. Johnston
  • Patent number: 7169596
    Abstract: This invention provides a novel isolated polynucleotide sequence, called ADARP1 (adenosine deaminase related protein 1), that displays significant homology to the adenosine deaminase (ADA) gene. Also provided is the amino acid sequence of the ADARP1 polypeptide encoded by the polynucleotide of the invention. The RNA for this novel gene is found in variety of tissues, with higher levels observed in the heart, testes, and skeletal muscle compared with others tested. Based on amino acid sequence homology, the ADARP1 protein will likely display the catalytic activity characteristic of ADA. This newly found ADARP1 gene and its encoded product may be useful in the treatment of immunodeficiencies, including severe combined immunodeficiency disease (SCID) and other ADA deficiencies, treatment of male reproductive disorders, testicular disorders and musclo-skeletal disorders.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: January 30, 2007
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Chandra S. Ramanathan, Gabe Mintier
  • Patent number: 7049096
    Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: May 23, 2006
    Assignee: Bristol-Meyers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier, David Bol, Donald R. Hawken
  • Patent number: 7045540
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary incontinence; and type II diabetes, as well as, pharmaceutical compositions comprising at least one compound of the present invention.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: May 16, 2006
    Assignee: Bristol Meyers Squibb Company
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 6919358
    Abstract: Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: July 19, 2005
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Peter T. Cheng, Pratik Devasthale, Yoon Jeon, Sean Chen, Hao Zhang
  • Patent number: 6642041
    Abstract: The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: November 4, 2003
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Jian Chen, John N. Feder, Thomas C. Nelson, Stanley R. Krystek, Franck Duclos
  • Patent number: 6223943
    Abstract: A container for dispensing two flowable products in desired proportions includes a multichamber squeeze tube with a pair of nested tubes and a dispensing neck on it that are integrally molded with a transverse wall as a single piece. Apertures in the end wall provide dispensing openings for a first chamber inside the inner tube, and for a second chamber between the two tubes. The transverse wall has an annular stepped wall portion in it between the two tubes that is generally parallel with the outer surface of the dispensing neck and has a dispensing opening through the stepped wall portion. The openings through the stepped wall are formed by parting line contact between the mold surfaces of the mold used to form the squeeze tube. The single piece, two chamber squeeze tube is molded in a straight draw mold with a split mold piece only required to release external threads formed on the neck. A cap with internal threads screws onto the threaded neck.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 1, 2001
    Assignees: Bristol-Meyers Squibb Company, RXI Plastics, Inc.
    Inventors: Thomas Michael Richmond, Thomas F. Wiegner
  • Patent number: 6143232
    Abstract: A method of manufacturing an articulating bearing surface for use in an orthopaedic implant uses a supply of ultra-high molecular weight polyethylene particles which are irradiated with sufficient radiation energy to crosslink at least a portion of the ultra-high molecular weight polyethylene. The irradiated particles are then formed into an orthopaedic bearing surface.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: November 7, 2000
    Assignee: Bristol-Meyers Squibb Company
    Inventor: William Rohr
  • Patent number: 6093712
    Abstract: Provided are cephem derivatives represented by the general formula ##STR1## wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.10 are as defined in the application. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: July 25, 2000
    Assignee: Bristol-Meyers Squibb Company
    Inventors: John D. Matiskella, Stanley V. D'Andrea, Thomas W. Hudyma, Yasutsugu Ueda, Oak K. Kim, Raymond F. Miller, Shelley E. Hoeft, Joanne J. Bronson
  • Patent number: 6010902
    Abstract: The present invention relates to novel antibody heteroconjugates and bispecific antibodies and methods and compositions and their use in the enhancement or inhibition of activation and function of T or B lymphocytes. The heteroconjugates are comprised of at least two antibody molecules cross-linked to each other, each molecule being reactive with a different lymphocyte antigen on the same cell. The invention also provides bispecific antibodies comprising a first binding region reactive with an antigen on a lymphocyte and a second binding region reactive with a different antigen on the lymphocyte. The heteroconjugates, bispecific antibodies, methods and compositions of this invention are therefore useful in the regulation of lymphocyte function, resulting in the improvement of cellular immune responses in various disease states.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: January 4, 2000
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Lisa K. Gilliland
  • Patent number: 5990110
    Abstract: A method is provided for treating hematologic tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an MTP inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematologic tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: November 23, 1999
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Raymond A. Firestone